Khan Taimoor A, Sadiq Muhammad Zeshan, Khan Ali A, Zahid Muhammad A, Zameer Sheharyar
Ophthalmology, National University of Medical Sciences (NUMS) Rawalpindi, Rawalpindi, PAK.
Ophthalmology, Armed Forces Institute of Ophthalmology Rawalpindi, Rawalpindi, PAK.
Cureus. 2024 Aug 14;16(8):e66885. doi: 10.7759/cureus.66885. eCollection 2024 Aug.
Ocular myasthenia gravis (OMG) is a neuromuscular disease characterized by the production of autoantibodies against post-synaptic proteins at the neuromuscular junction (NMJ). An 18-year-old male who had symptoms of drooping eyelids and double vision was diagnosed with ocular myasthenia gravis on investigations and examinations. Treatment was initiated with a tablet of pyridostigmine 60 mg twice daily per oral for two weeks, followed by three times daily for four weeks. The patient demonstrated significant improvement in ptosis and diplopia. There are still a considerable number of challenges in the diagnosis and treatment of ocular myasthenia gravis, with the typical treatment involving acetylcholinesterase inhibitors and immunosuppressants.
眼肌型重症肌无力（OMG）是一种神经肌肉疾病，其特征是在神经肌肉接头（NMJ）处产生针对突触后蛋白的自身抗体。一名18岁男性出现眼睑下垂和复视症状，经检查诊断为眼肌型重症肌无力。开始治疗时，口服吡啶斯的明片，每日两次，每次60毫克，持续两周，之后每日三次，持续四周。患者的上睑下垂和复视症状有显著改善。眼肌型重症肌无力的诊断和治疗仍存在相当多的挑战，典型治疗包括使用乙酰胆碱酯酶抑制剂和免疫抑制剂。
